Paris-based medtech company Sonomind, which develops ultrasound-based devices for brain disorder treatment, has raised €3 million in a seed round to begin clinical trials for drug-resistant depression, as Vestbee was informed.
- Launched in 2024 by Jérémy Bercoff, Mickael Tanter, and Jean-François Aubry, Sonomind develops a medical device for non-invasive, personalized neuromodulation using low-intensity ultrasound.
- The system delivers ultrasound waves through a patient-specific acoustic lens that compensates for skull variations, allowing precise targeting of deep brain regions involved in depression and other neuropsychiatric disorders.
- The technology is designed to modulate brain activity without invasive procedures, with early clinical studies showing reductions in depressive symptoms over a short treatment period. The device also provides data on treatment effects, enabling clinicians to track and adjust therapy for each patient.
Details of the deal
- Sonomind raised €3 million in its funding round, with €2 million from Critical Path Ventures and €1 million in non-dilutive support from the French Government through Bpifrance.
“Sonomind is developing a truly groundbreaking innovation in psychiatry. This approach was instrumental in our choice to support Sonomind. Mental health remains one of the world’s most pressing public health concerns, representing a market valued at $500 billion, where treatment resistance continues to be a significant challenge," explains Nicolas Foessel, CEO of Critical Path Ventures.
- The firm aims to use the fresh capital to begin clinical trials in patients with drug-resistant depression and to finalize the development of its non-invasive, personalized ultrasound-based neuromodulation technology.
“This brings us one step closer to our mission of providing an effective treatment for the millions of people living with depression—transforming a lifelong struggle into a renewed chance at life. Our ambition is to enable rapid, precise and side-effect-free treatment," claims Jeremy Bercoff, co-founder and president of Sonomind.
